DEFINITY
Total Payments
$4.3M
Transactions
10,700
Doctors
4,548
Companies
3
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $535,223 | 2,092 | 1,271 |
| 2023 | $920,676 | 2,696 | 1,584 |
| 2022 | $964,817 | 2,460 | 1,388 |
| 2021 | $693,368 | 2,018 | 1,058 |
| 2020 | $1.1M | 1,393 | 694 |
| 2019 | $61,822 | 41 | 8 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.9M | 998 | 43.1% |
| Unspecified | $1.6M | 246 | 37.9% |
| Travel and Lodging | $261,164 | 963 | 6.0% |
| Food and Beverage | $257,689 | 8,334 | 6.0% |
| Consulting Fee | $164,999 | 35 | 3.8% |
| Space rental or facility fees (teaching hospital only) | $74,750 | 33 | 1.7% |
| Debt forgiveness | $34,244 | 39 | 0.8% |
| Grant | $19,500 | 3 | 0.5% |
| Gift | $7,878 | 8 | 0.2% |
| Education | $470.44 | 41 | 0.0% |
Payments by Type
General
$2.7M
10,454 transactions
Research
$1.6M
246 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| DEF-315 Better Accuracy in EF Assessment With DEFINITY (BENEFIT2) | Lantheus Medical Imaging, Inc. | $400,117 | 0 |
| DEF-314 Better Accuracy in EF Assessment With DEFINITY (BENEFIT1) | Lantheus Medical Imaging, Inc. | $192,315 | 0 |
| Ultrasound Cavitation for Treating Non-healing Ischemic Ulcers in Patients with Critical Limb Ischemia | Lantheus Medical Imaging, Inc. | $84,398 | 0 |
| UTILIZATION OF ULTRASOUND ENHANCING AGENTS IN A NATIONWIDE COHORT | LANTHEUS MEDICAL IMAGING, INC. | $72,460 | 0 |
| Contrast-Enhanced Ultrasound for Kidney Cancer Subtyping and Staging | Lantheus Medical Imaging, Inc. | $59,321 | 0 |
| Quantitative Subharmonic Breast Imaging: 3D Subharmonic Pressure Estimation for Prediction of Neoadjuvant Chemotherapy Response | Lantheus Medical Imaging, Inc. | $58,553 | 0 |
| ULTRASOUND CAVITATION FOR TREATING NON-HEALING ISCHEMIC ULCERS IN PATIENTS WITH CRITICAL LIMB ISCHEMIA | LANTHEUS MEDICAL IMAGING, INC. | $56,963 | 0 |
| QUANTITATIVE SUBHARMONIC BREAST IMAGING 3D SUBHARMONIC PRESSURE ESTIMATION FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE | LANTHEUS MEDICAL IMAGING, INC. | $52,915 | 0 |
| Microvascular Recovery with Ultrasound in Acute Myocardial Infarction Trial Post PCI Trial | Lantheus Medical Imaging, Inc. | $52,646 | 0 |
| QUANTITATIVE SUBHARMONIC BREAST IMAGING: 3D SUBHARMONIC PRESSURE ESTIMATION FOR PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE | Lantheus Medical Imaging, Inc. | $45,723 | 0 |
| NONINVASIVE SUBHARMONIC AIDED PRESSURE ESTIMATION OF PORTAL HYPERTENSION | Lantheus Medical Imaging, Inc. | $32,863 | 0 |
| Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier Disruption for the Treatment of High Grade Glioma in Patients Undergoing Standard Chemotherapy | Lantheus Medical Imaging, Inc. | $27,326 | 0 |
| ULTRASOUND CAVITATION FOR TREATING NON-HEALING ISCHEMIC ULCERS IN PATIENTS WITH CRITICAL LIMB ISCHEMIA | Lantheus Medical Imaging, Inc. | $24,290 | 0 |
| UTILIZATION OF ULTRASOUND ENHANCING AGENTS IN A NATIONWIDE COHORT | Lantheus Medical Imaging, Inc. | $24,153 | 0 |
| Sex-related differences in arterial stiffness in type 2 diabetics: role of uric acid | Lantheus Medical Imaging, Inc. | $22,883 | 0 |
| A FEASIBILITY STUDY EXAMINING THE USE OF NON-INVASIVE FOCUSED ULTRASOUND (FUS) WITH ORAL ETOPOSIDE ADMINISTRATION IN CHILDREN WITH PROGRESSIVE DIFFUSE MIDLINE GLIOMA (DMG) | Lantheus Medical Imaging, Inc. | $22,861 | 0 |
| 2D and 4D Contrast-Ultrasound Evaluation of Hepatocellular Carcinoma Chemoembolization | Lantheus Medical Imaging, Inc. | $22,749 | 0 |
| Microvascular Effects of Long Duration Space Missions | Lantheus Medical Imaging, Inc. | $21,168 | 0 |
| (RTMPE in the ICU) The Impact of Real-Time Myocardial Perfusion Echocardiography on Diagnostic Confidence and Subsequent Management of Myocardial Ischemia in the Intensive Care Unit | Lantheus Medical Imaging, Inc. | $20,000 | 0 |
| Cross-Sectional Study of Contrast-Enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients with Von Hippel-Lindau | Lantheus Medical Imaging, Inc. | $19,789 | 0 |
Top Doctors Receiving Payments for DEFINITY
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Springfield, MO | $1.8M | 319 |
| , M.D | Cardiovascular Disease | New York, NY | $468,130 | 709 |
| , D.O | Internal Medicine | Tucson, AZ | $241,627 | 241 |
| , MD | Cardiovascular Disease | Pittsburgh, PA | $199,593 | 234 |
| , M.D | Cardiovascular Disease | Salt Lake City, UT | $166,120 | 261 |
| , MD, MRCP, FACC, FASE | Internal Medicine | Tucson, AZ | $151,285 | 176 |
| , M.D | Cardiovascular Disease | Fort Worth, TX | $131,289 | 133 |
| , MD | Internal Medicine | Columbus, OH | $77,486 | 103 |
| , M.D | Specialist | New York, NY | $74,471 | 68 |
| , MD | Health Service | Washington, DC | $58,508 | 10 |
| , M.D | Cardiovascular Disease | Chicago, IL | $50,720 | 47 |
| , DO | Internal Medicine | Bloomfield Hills, MI | $49,977 | 51 |
| , M.D | Hospitalist | Nashville, TN | $49,553 | 39 |
| , M.D | Interventional Cardiology | Paducah, KY | $46,325 | 48 |
| , NP | Acute Care | Murray, UT | $42,758 | 81 |
| , M.D | Internal Medicine | Munster, IN | $41,044 | 34 |
| , MD | Cardiovascular Disease | Long Beach, CA | $33,921 | 41 |
| , MD | Cardiovascular Disease | Windermere, FL | $32,257 | 31 |
| Hari Gnanasekeram | — | Philadelphia, PA | $30,429 | 40 |
| , MD | Cardiovascular Disease | Chicago, IL | $28,710 | 33 |
| , M.D | Cardiovascular Disease | Kyle, TX | $26,916 | 36 |
| , M.D | Cardiovascular Disease | Manchester, NH | $23,927 | 39 |
| , M.D | Cardiovascular Disease | Roslyn, NY | $23,769 | 34 |
| , M.D | Interventional Cardiology | Berkley, MI | $19,520 | 18 |
| , MD | Pediatric Cardiology | Baltimore, MD | $18,778 | 6 |
Ad
Manufacturing Companies
- Lantheus Medical Imaging, Inc. $3.6M
- LANTHEUS MEDICAL IMAGING, INC. $677,897
- Hologic, LLC $74.90
Product Information
- Type Drug
- Total Payments $4.3M
- Total Doctors 4,548
- Transactions 10,700
About DEFINITY
DEFINITY is a drug associated with $4.3M in payments to 4,548 healthcare providers, recorded across 10,700 transactions in the CMS Open Payments database. The primary manufacturer is Lantheus Medical Imaging, Inc..
Payment data is available from 2019 to 2024. In 2024, $535,223 was paid across 2,092 transactions to 1,271 doctors.
The most common payment nature for DEFINITY is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($1.9M, 43.1% of total).
DEFINITY is associated with 20 research studies, including "DEF-315 Better Accuracy in EF Assessment With DEFINITY (BENEFIT2)" ($400,117).